Small Interfering RNAs (siRNA) Molecule Type Segment Held Largest Share of RNAi Therapeutics in 2019
According to the new market research study on “North America RNAi Therapeutics Market to 2027 - Regional Analysis and Forecast - by Molecule Type, Route of Administration, Application, and End User” the North America RNAi therapeutics market is expected to reach US$598.60 million in 2027 from US$302.77 million in 2019, it is estimated to grow with a CAGR of 9.0% from 2020-2027. The report provides trends prevailing in the North America RNAi therapeutics market and the factors driving the market growth along with those hindering it.
In 2019, the small interfering RNAs (siRNA) accounted for the highest share of the market. Growth of this segment is attributed to the increasing preference for small interfering RNAs for drug development and growing number of research partnerships. Furthermore, MicroRNA (miRNA) segment is expected to register higher CAGR in the RNAi therapeutics market during the forecast period.
The growth of the North America RNAi therapeutics market is mainly attributed to growing prevalence of chronic conditions and rising investments for development of RNAi therapeutics. Additionally, increasing awareness about RNAi therapies and its benefits are anticipated to boost the research and innovations of RNAi therapeutics in the region will eventually drive the market growth. However, the high cost of RNAi therapy development is the major factor hindering the market growth in North America.
Alnylam Pharmaceuticals, Inc; Arrowhead Pharmaceuticals, Inc; Quark; Rexahn Pharmaceuticals, Inc; and Arbutus Biopharma are among the leading companies operating in the North America RNAi therapeutics market.
The Report Segments North America RNAi Therapeutics Market as Follows:
By Molecule Type
By Route of Administration
By Application
By End User
By Country
Reasons to Buy
According to the new market research study on “North America RNAi Therapeutics Market to 2027 - Regional Analysis and Forecast - by Molecule Type, Route of Administration, Application, and End User” the North America RNAi therapeutics market is expected to reach US$598.60 million in 2027 from US$302.77 million in 2019, it is estimated to grow with a CAGR of 9.0% from 2020-2027. The report provides trends prevailing in the North America RNAi therapeutics market and the factors driving the market growth along with those hindering it.
In 2019, the small interfering RNAs (siRNA) accounted for the highest share of the market. Growth of this segment is attributed to the increasing preference for small interfering RNAs for drug development and growing number of research partnerships. Furthermore, MicroRNA (miRNA) segment is expected to register higher CAGR in the RNAi therapeutics market during the forecast period.
The growth of the North America RNAi therapeutics market is mainly attributed to growing prevalence of chronic conditions and rising investments for development of RNAi therapeutics. Additionally, increasing awareness about RNAi therapies and its benefits are anticipated to boost the research and innovations of RNAi therapeutics in the region will eventually drive the market growth. However, the high cost of RNAi therapy development is the major factor hindering the market growth in North America.
Alnylam Pharmaceuticals, Inc; Arrowhead Pharmaceuticals, Inc; Quark; Rexahn Pharmaceuticals, Inc; and Arbutus Biopharma are among the leading companies operating in the North America RNAi therapeutics market.
The Report Segments North America RNAi Therapeutics Market as Follows:
By Molecule Type
- Small Interfering RNAs (siRNA)
- MicroRNA (miRNA)
By Route of Administration
- Pulmonary Delivery
- Intravenous Injections
- Intradermal Injections
- Intraperitoneal Injections
- Others
By Application
- Oncology
- Cardiovascular
- Respiratory Disorders
- Renal Diseases
- Genetic Disorders
- Neurodegenerative Disorders
- Infectious Diseases
- Others
By End User
- Research and Academic Laboratories
- Hospitals
- Diagnostic Laboratories
By Country
- US
- Canada
- Mexico
Reasons to Buy
- It provides an understanding of the North America, RNAi therapeutics market landscape and identifies RNAi therapeutics market segments that are most likely to guarantee a strong return.
- Stay ahead of the race by comprehending the ever-changing competitive landscape for the North America RNAi therapeutics market.
- It helps efficiently plan merger and acquisition, and partnership deals in the RNAi therapeutics market by identifying market segments with the most promising probable sales
- It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of RNAi therapeutics market performance of various segments pertaining to the North America RNAi therapeutics market.
- It provides RNAi therapeutics market revenue forecast of the market based on various segments for the period from 2019 to 2027.
Table of Contents
1. Introduction
3. Research Methodology
4. North America RNAi Therapeutics Market - Market Landscape
5. North America RNAi Therapeutics Market - Key Market Dynamics
6. RNAi Therapeutics Market - North America Analysis
7. North America RNAi Therapeutics Market Analysis and Forecasts To 2027 - By Molecule Type
8. North America RNAi therapeutics Market Analysis and Forecasts To 2027 - By Application
9. North America RNAi therapeutics Market Analysis and Forecasts To 2027 - By Route of Administration
10. North America RNAi Therapeutics Market Analysis - By End-User
11. RNAi therapeutics Market Revenue and Forecasts To 2027 - Geographical Analysis
12. Impact of COVID-19 Pandemic on North America RNAi therapeutics Market
13. Company Profiles
14. Appendix
List of Tables
List of Figures
Companies Mentioned
A selection of companies mentioned in this report includes:
- Alnylam Pharmaceuticals, Inc
- Arrowhead Pharmaceuticals, Inc
- Quark
- Rexahn Pharmaceuticals, Inc
- Arbutus Biopharma